CATX
Perspective Therapeutics, Inc.
Price Chart
Latest Quote
$2.95
-0.03 (-1.01%)
Current Price
| Previous Close | $2.98 |
| Open | $3.02 |
| Day High | $3.13 |
| Day Low | $2.93 |
| Volume | 7,664,259 |
Stock Information
| Shares Outstanding | 114.05M |
| Total Debt | $4.23M |
| Cash Equivalents | $270.93M |
| Revenue | $618K |
| Net Income | $-111.65M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $336.44M |
| EPS (TTM) | $-1.41 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $67.46M |
| Sales | $618K |
| Income | $-111.65M |
| Book/sh | $3.05 |
| Cash/sh | $2.38 |
| Employees | 163 |
Financial Ratios
| Quick Ratio | 8.61 |
| Current Ratio | 8.74 |
| Debt/Eq | 1.22 |
Returns & Margins
| ROA | -20.27% |
| ROE | -35.33% |
| Operating Margin | -37211.84% |
Ownership
| Insider Ownership | 10.81% |
| Institutional Ownership | 76.65% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.60 |
| P/S | 544.40 |
| P/B | 0.97 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $12.93 |
Technical Indicators
| SMA20 | $3.39 |
| SMA50 | $3.80 |
| SMA200 | $3.60 |
| RSI | 11.02 |
| ATR | 0.2093 |
| Shares Float | 74.34M |
| Short Float | 13.37% |
| Short Ratio | 9.38 |
| Volatility | 1.73 |
| Rel Volume | 4.44 |
Performance History
| Week | -0.67% |
| Month | -18.73% |
| Quarter | -35.87% |
| 6 Months | +3.87% |
| YTD | +5.73% |
| Year | -16.43% |
| 3 Years | -46.36% |
| 5 Years | -66.09% |
| 10 Years | -63.12% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.95 | 7,664,300 |
| 2026-06-17 | $2.98 | 2,046,600 |
| 2026-06-16 | $2.93 | 765,500 |
| 2026-06-15 | $2.94 | 1,758,400 |
| 2026-06-12 | $2.95 | 1,027,200 |
| 2026-06-11 | $2.97 | 1,052,800 |
| 2026-06-10 | $2.95 | 1,141,300 |
| 2026-06-09 | $3.00 | 1,491,100 |
| 2026-06-08 | $2.93 | 1,263,100 |
| 2026-06-05 | $3.03 | 1,858,800 |
| 2026-06-04 | $3.25 | 3,630,000 |
| 2026-06-03 | $3.56 | 982,200 |
| 2026-06-02 | $3.60 | 1,006,100 |
| 2026-06-01 | $3.66 | 1,478,800 |
| 2026-05-29 | $3.94 | 893,500 |
| 2026-05-28 | $4.05 | 1,254,800 |
| 2026-05-27 | $4.16 | 1,029,100 |
| 2026-05-26 | $4.16 | 1,521,700 |
| 2026-05-22 | $3.98 | 1,717,300 |
| 2026-05-21 | $3.87 | 918,700 |
| 2026-05-20 | $3.77 | 825,700 |
| 2026-05-19 | $3.63 | 882,200 |
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
đ° Latest News
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Proactive âĸ 2026-06-03T18:06:00Z
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T23:05:14Z
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress
Insider Monkey âĸ 2026-02-18T01:42:31Z
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies â Has The Bull Case Changed?
Simply Wall St. âĸ 2026-02-04T06:12:25Z
A Look At Perspective Therapeutics (CATX) Valuation After New VMT-Îą-NET Trial And Pipeline Updates
Simply Wall St. âĸ 2026-02-02T02:08:29Z
Perspective Therapeutics: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-10T21:27:35ZStevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Zacks âĸ 2025-11-06T12:45:03Z
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
Zacks âĸ 2025-11-04T22:25:03Z
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
Zacks âĸ 2025-10-29T12:15:03Z
Could CATXâs New ESMO Data Reveal a Shift in Its Long-Term Oncology Innovation Strategy?
Simply Wall St. âĸ 2025-10-21T06:07:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $10,795,000 |
| Operating Revenue | $0 | $0 | $0 | $10,795,000 |
| Reconciled Cost Of Revenue | - | - | - | $6,179,000 |
| Cost Of Revenue | - | - | - | $6,179,000 |
| Expenses | ||||
| Interest Expense | $376,000 | $48,000 | $82,000 | - |
| Total Expenses | $113,564,000 | $66,797,000 | $40,941,000 | $18,186,000 |
| Other Income Expense | $1,398,000 | $-24,097,000 | $-17,000 | - |
| Other Non Operating Income Expenses | $1,400,000 | - | $2,000 | - |
| Net Non Operating Interest Income Expense | $7,738,000 | $10,467,000 | $852,000 | $119,000 |
| Interest Expense Non Operating | $376,000 | $48,000 | $82,000 | - |
| Operating Expense | $113,564,000 | $66,797,000 | $40,941,000 | $12,007,000 |
| Other Operating Expenses | $-884,000 | $-1,454,000 | $-1,434,000 | - |
| General And Administrative Expense | $30,233,000 | $26,613,000 | $21,064,000 | $6,668,000 |
| Selling And Marketing Expense | - | - | - | $2,757,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-103,635,000 | $-78,330,000 | $-37,455,000 | $-7,272,000 |
| Net Interest Income | $7,738,000 | $10,467,000 | $852,000 | $119,000 |
| Interest Income | $8,114,000 | $10,515,000 | $934,000 | $119,000 |
| Normalized Income | $-103,635,000 | $-54,867,314 | $-37,455,000 | $-7,272,000 |
| Net Income From Continuing And Discontinued Operation | $-103,121,000 | $-79,279,000 | $-46,508,000 | $-7,272,000 |
| Total Operating Income As Reported | $-113,564,000 | $-90,886,000 | $-40,941,000 | $-7,391,000 |
| Net Income Common Stockholders | $-103,121,000 | $-79,279,000 | $-46,508,000 | $-7,272,000 |
| Net Income | $-103,121,000 | $-79,279,000 | $-46,508,000 | $-7,272,000 |
| Net Income Including Noncontrolling Interests | $-103,121,000 | $-79,279,000 | $-46,508,000 | $-7,272,000 |
| Net Income Discontinuous Operations | $514,000 | $-949,000 | $-9,053,000 | - |
| Net Income Continuous Operations | $-103,635,000 | $-78,330,000 | $-37,455,000 | $-7,272,000 |
| Pretax Income | $-104,428,000 | $-80,427,000 | $-40,106,000 | $-7,272,000 |
| Special Income Charges | $0 | $-24,089,000 | $0 | $0 |
| Earnings From Equity Interest | $-2,000 | $-8,000 | $-17,000 | - |
| Interest Income Non Operating | $8,114,000 | $10,515,000 | $934,000 | $119,000 |
| Operating Income | $-113,564,000 | $-66,797,000 | $-40,941,000 | $-7,391,000 |
| Gross Profit | - | - | - | $4,616,000 |
| Per Share | ||||
| Diluted EPS | $-1.40 | $-1.23 | $-1.74 | $-0.50 |
| Basic EPS | $-1.40 | $-1.23 | $-1.74 | $-0.50 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-626,314 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-100,801,000 | $-53,984,000 | $-39,038,000 | $-7,143,000 |
| Total Unusual Items | $0 | $-24,089,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $-24,089,000 | $0 | $0 |
| Reconciled Depreciation | $3,251,000 | $2,306,000 | $986,000 | $248,000 |
| EBITDA (Bullshit earnings) | $-100,801,000 | $-78,073,000 | $-39,038,000 | $-7,143,000 |
| EBIT | $-104,052,000 | $-80,379,000 | $-40,024,000 | $-7,391,000 |
| Diluted Average Shares | $73,813,000 | $64,425,000 | $26,764,000 | $14,198,700 |
| Basic Average Shares | $73,813,000 | $64,425,000 | $26,764,000 | $14,198,700 |
| Diluted NI Availto Com Stockholders | $-103,121,000 | $-79,279,000 | $-46,508,000 | $-7,272,000 |
| Tax Provision | $-793,000 | $-2,097,000 | $-2,651,000 | - |
| Gain On Sale Of Ppe | $0 | $-27,000 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $24,062,000 | $0 | - |
| Research And Development | $84,215,000 | $41,638,000 | $21,311,000 | $2,582,000 |
| Selling General And Administration | $30,233,000 | $26,613,000 | $21,064,000 | $9,425,000 |
| Other Gand A | $30,233,000 | $26,613,000 | $21,064,000 | $5,905,000 |
| Salaries And Wages | - | - | - | $763,000 |
| Preferred Stock Dividends | - | - | - | - |
Fetched: 2026-06-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $167,027,000 | $240,657,000 | $763,000 | $61,170,000 |
| Total Assets | $266,972,000 | $341,101,000 | $97,891,000 | $64,439,000 |
| Total Non Current Assets | $118,583,000 | $109,941,000 | $81,054,000 | $5,110,000 |
| Non Current Prepaid Assets | $207,000 | $72,000 | $0 | - |
| Goodwill And Other Intangible Assets | $40,004,000 | $50,011,000 | $74,416,000 | $107,000 |
| Other Intangible Assets | $40,004,000 | $50,011,000 | $50,354,000 | $107,000 |
| Current Assets | $148,389,000 | $231,160,000 | $16,837,000 | $59,329,000 |
| Other Current Assets | $35,000 | $81,000 | $45,000 | $27,000 |
| Prepaid Assets | $2,578,000 | $2,680,000 | $1,078,000 | $391,000 |
| Receivables | $1,039,000 | $1,483,000 | $1,175,000 | $1,625,000 |
| Other Receivables | $10,000 | $487,000 | $10,000 | $17,000 |
| Accrued Interest Receivable | $1,023,000 | $880,000 | $0 | - |
| Accounts Receivable | $6,000 | $116,000 | $1,165,000 | $1,608,000 |
| Allowance For Doubtful Accounts Receivable | $-375,000 | $-543,000 | $-650,000 | $-26,000 |
| Gross Accounts Receivable | $381,000 | $659,000 | $1,815,000 | $1,634,000 |
| Cash Cash Equivalents And Short Term Investments | $144,737,000 | $226,916,000 | $9,238,000 | $55,890,000 |
| Cash And Cash Equivalents | $30,629,000 | $61,580,000 | $9,238,000 | $55,890,000 |
| Assets Held For Sale Current | - | $0 | $5,301,000 | - |
| Other Non Current Assets | - | - | $182,000 | $2,515,000 |
| Notes Receivable | - | - | $0 | $0 |
| Inventory | - | - | - | $1,396,000 |
| Debt | ||||
| Total Debt | $3,253,000 | $4,062,000 | $2,551,000 | $524,000 |
| Long Term Debt And Capital Lease Obligation | $2,574,000 | $3,053,000 | $2,456,000 | $256,000 |
| Long Term Debt | $1,569,000 | $1,625,000 | $1,676,000 | - |
| Current Debt And Capital Lease Obligation | $679,000 | $1,009,000 | $95,000 | $268,000 |
| Current Debt | $56,000 | $52,000 | $49,000 | - |
| Other Current Borrowings | $56,000 | $52,000 | $49,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $59,941,000 | $50,433,000 | $22,712,000 | $3,162,000 |
| Total Non Current Liabilities Net Minority Interest | $31,262,000 | $32,203,000 | $7,048,000 | $896,000 |
| Other Non Current Liabilities | $386,000 | $55,000 | - | - |
| Non Current Deferred Liabilities | $28,302,000 | $29,095,000 | $4,592,000 | - |
| Non Current Deferred Taxes Liabilities | $1,702,000 | $2,495,000 | $4,592,000 | - |
| Current Liabilities | $28,679,000 | $18,230,000 | $15,664,000 | $2,266,000 |
| Current Deferred Liabilities | $0 | $1,400,000 | $0 | - |
| Payables And Accrued Expenses | $20,511,000 | $10,343,000 | $6,909,000 | $1,745,000 |
| Payables | $20,511,000 | $10,343,000 | $6,909,000 | $966,000 |
| Accounts Payable | $20,511,000 | $10,343,000 | $6,909,000 | $966,000 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | - |
| Other Current Liabilities | - | - | $5,072,000 | - |
| Equity | ||||
| Common Stock Equity | $207,031,000 | $290,668,000 | $75,179,000 | $61,277,000 |
| Total Equity Gross Minority Interest | $207,031,000 | $290,668,000 | $75,179,000 | $61,277,000 |
| Stockholders Equity | $207,031,000 | $290,668,000 | $75,179,000 | $61,277,000 |
| Gains Losses Not Affecting Retained Earnings | $110,000 | $-51,000 | $0 | - |
| Other Equity Adjustments | $110,000 | $-51,000 | - | - |
| Retained Earnings | $-334,840,000 | $-231,719,000 | $-152,440,000 | $-98,597,000 |
| Long Term Equity Investment | $275,000 | $322,000 | $133,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $74,337,990 | $70,671,464 | $28,180,985 | $14,204,026 |
| Share Issued | $74,337,990 | $70,671,464 | $28,180,985 | $14,204,026 |
| Tangible Book Value | $167,027,000 | $240,657,000 | $763,000 | $61,170,000 |
| Invested Capital | $208,656,000 | $292,345,000 | $76,904,000 | $61,277,000 |
| Working Capital | $119,710,000 | $212,930,000 | $1,173,000 | $57,063,000 |
| Capital Lease Obligations | $1,628,000 | $2,385,000 | $826,000 | $524,000 |
| Total Capitalization | $208,600,000 | $292,293,000 | $76,855,000 | $61,277,000 |
| Additional Paid In Capital | $541,687,000 | $522,368,000 | $227,591,000 | $159,732,000 |
| Capital Stock | $74,000 | $70,000 | $28,000 | $142,000 |
| Common Stock | $74,000 | $70,000 | $28,000 | $142,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $26,600,000 | $26,600,000 | $0 | - |
| Long Term Capital Lease Obligation | $1,005,000 | $1,428,000 | $780,000 | $256,000 |
| Current Deferred Revenue | $0 | $1,400,000 | $0 | - |
| Current Capital Lease Obligation | $623,000 | $957,000 | $46,000 | $268,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,489,000 | $5,478,000 | $3,588,000 | $253,000 |
| Investments And Advances | $275,000 | $322,000 | $133,000 | $0 |
| Net PPE | $78,097,000 | $59,536,000 | $6,323,000 | $2,488,000 |
| Accumulated Depreciation | $-6,204,000 | $-2,960,000 | $-669,000 | $-7,496,000 |
| Gross PPE | $84,301,000 | $62,496,000 | $6,992,000 | $9,984,000 |
| Leases | $3,864,000 | $3,570,000 | $179,000 | $4,143,000 |
| Other Properties | $77,750,000 | $56,239,000 | $3,760,000 | $5,475,000 |
| Buildings And Improvements | $1,770,000 | $1,770,000 | $1,770,000 | - |
| Land And Improvements | $917,000 | $917,000 | $1,283,000 | $366,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $114,108,000 | $165,336,000 | $0 | $0 |
| Goodwill | - | $0 | $24,062,000 | - |
| Treasury Shares Number | - | - | $0 | - |
| Current Accrued Expenses | - | - | $3,930,000 | $779,000 |
| Non Current Accrued Expenses | - | - | - | $0 |
| Long Term Provisions | - | - | - | $640,000 |
| Finished Goods | - | - | - | $23,000 |
| Work In Process | - | - | - | $462,000 |
| Raw Materials | - | - | - | $911,000 |
| Treasury Stock | - | - | - | - |
Fetched: 2026-06-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-95,233,000 | $-72,708,000 | $-37,985,000 | $-7,976,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-82,484,000 | $-18,294,000 | $-36,913,000 | $-7,710,000 |
| Cash Flow From Continuing Operating Activities | $-82,484,000 | $-18,294,000 | $-36,913,000 | $-7,710,000 |
| Operating Gains Losses | $250,000 | $21,000 | $22,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-12,749,000 | $-54,414,000 | $-1,072,000 | $-266,000 |
| Investing Cash Flow | $41,228,000 | $-218,931,000 | $24,373,000 | $-284,000 |
| Cash Flow From Continuing Investing Activities | $41,228,000 | $-218,931,000 | $24,373,000 | $-284,000 |
| Net Other Investing Changes | $-135,000 | $-72,000 | $-18,000 | $-18,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,986,000 | $288,180,000 | $364,000 | $0 |
| Financing Cash Flow | $10,305,000 | $289,385,000 | $785,000 | $56,000 |
| Cash Flow From Continuing Financing Activities | $10,305,000 | $289,385,000 | $785,000 | $56,000 |
| Net Common Stock Issuance | $9,986,000 | $288,180,000 | $364,000 | $0 |
| Common Stock Issuance | $9,986,000 | $288,180,000 | $364,000 | $0 |
| Net Other Financing Charges | - | - | $-65,000 | - |
| Cash Dividends Paid | - | - | - | $0 |
| Preferred Stock Dividend Paid | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-52,000 | $-48,000 | $-68,000 | - |
| End Cash Position | $30,629,000 | $61,580,000 | $9,420,000 | $56,072,000 |
| Beginning Cash Position | $61,580,000 | $9,420,000 | $21,175,000 | $64,010,000 |
| Changes In Cash | $-30,951,000 | $52,160,000 | $-11,755,000 | $-7,938,000 |
| Proceeds From Stock Option Exercised | $371,000 | $1,253,000 | $554,000 | $56,000 |
| Net Issuance Payments Of Debt | $-52,000 | $-48,000 | $-68,000 | - |
| Net Long Term Debt Issuance | $-52,000 | $-48,000 | $-68,000 | - |
| Long Term Debt Payments | $-52,000 | $-48,000 | $-68,000 | - |
| Net Investment Purchase And Sale | $54,112,000 | $-164,780,000 | $22,764,000 | $0 |
| Sale Of Investment | $173,950,000 | $78,730,000 | $22,764,000 | $0 |
| Purchase Of Investment | $-119,838,000 | $-243,510,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-12,749,000 | $-54,079,000 | $-1,072,000 | $-266,000 |
| Sale Of PPE | $0 | $335,000 | $0 | $0 |
| Purchase Of PPE | $-12,749,000 | $-54,414,000 | $-1,072,000 | $-266,000 |
| Change In Working Capital | $1,681,000 | $31,814,000 | $2,920,000 | $-1,850,000 |
| Change In Other Working Capital | $-1,400,000 | $28,000,000 | - | - |
| Change In Other Current Liabilities | $331,000 | $55,000 | $0 | - |
| Change In Payables And Accrued Expense | $2,158,000 | $5,490,000 | $2,688,000 | $372,000 |
| Change In Accrued Expense | $2,011,000 | $3,600,000 | $1,115,000 | $136,000 |
| Change In Payable | $147,000 | $1,890,000 | $1,573,000 | $236,000 |
| Change In Account Payable | $147,000 | $1,890,000 | $1,573,000 | $236,000 |
| Change In Prepaid Assets | $624,000 | $-1,911,000 | $-325,000 | $46,000 |
| Change In Inventory | $0 | $11,000 | $359,000 | $-2,673,000 |
| Change In Receivables | $-32,000 | $169,000 | $198,000 | $405,000 |
| Changes In Account Receivables | $110,000 | $1,049,000 | $198,000 | - |
| Other Non Cash Items | $5,000 | $99,000 | $4,580,000 | $77,000 |
| Stock Based Compensation | $8,966,000 | $5,387,000 | $3,738,000 | $1,087,000 |
| Asset Impairment Charge | $10,000,000 | $24,062,000 | $0 | - |
| Amortization Of Securities | $-2,723,000 | $-607,000 | $0 | - |
| Deferred Tax | $-793,000 | $-2,097,000 | $-2,651,000 | - |
| Deferred Income Tax | $-793,000 | $-2,097,000 | $-2,651,000 | - |
| Depreciation Amortization Depletion | $3,251,000 | $2,306,000 | $986,000 | $248,000 |
| Depreciation And Amortization | $3,251,000 | $2,306,000 | $986,000 | $248,000 |
| Depreciation | $3,251,000 | $2,306,000 | $986,000 | $248,000 |
| Net Foreign Currency Exchange Gain Loss | $250,000 | $-65,000 | - | - |
| Gain Loss On Sale Of PPE | $0 | $27,000 | $22,000 | $0 |
| Gain Loss On Sale Of Business | $0 | $59,000 | - | - |
| Net Income From Continuing Operations | $-103,121,000 | $-79,279,000 | $-46,508,000 | $-7,272,000 |
| Net Business Purchase And Sale | - | $0 | $2,699,000 | - |
| Sale Of Business | - | $0 | $2,699,000 | - |
| Interest Paid Supplemental Data | - | - | $84,000 | - |
| Provisionand Write Offof Assets | - | - | $624,000 | - |
| Earnings Losses From Equity Investments | - | - | $17,000 | - |
| Amortization Cash Flow | - | - | - | $41,000 |
| Amortization Of Intangibles | - | - | - | $41,000 |
Fetched: 2026-06-13